Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Vasopressin antagonists].

P de Groote1

  • 1Service de cardiologie C, hôpital cardiologique, CHRU Lille, 59037 Lille. pdegroote@chru-lille.fr

Archives Des Maladies Du Coeur Et Des Vaisseaux
|April 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Tolerance of bevacizumab therapy in systemic sclerosis-associated pulmonary arterial hypertension: A case report].

La Revue de medecine interne·2016
Same author

A novel RIPK4-IRF6 connection is required to prevent epithelial fusions characteristic for popliteal pterygium syndromes.

Cell death and differentiation·2014
Same author

Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients.

Annals of the rheumatic diseases·2008
Same author

Treatment of heart failure with preserved systolic function.

Archives of cardiovascular diseases·2008
Same author

No gender survival difference in a population of patients with chronic heart failure related to left ventricular systolic dysfunction and receiving optimal medical therapy.

Archives of cardiovascular diseases·2008
Same author

[Treating heart failure with carvedilol in private practice (initiating treatment and follow-up at one year. The KEOPS study].

Archives des maladies du coeur et des vaisseaux·2007
Same journal

Radiokymographic study of the kinetics of the middle arc and the hils in the normal subject.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

A medication for angina pectoris and pre-fibrillatory conditions; 1262 F; six years of clinical experience; action mechanism.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Circulatory changes following the injection of hypertonic saline solutions; application to the study of angina pectoris.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Alterations in coronary circulation during aortic insufficiency in young subjects.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Cardio-esophageal auscultation.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Hypertensive accidents following the injection of acetylcholine.

Archives des maladies du coeur et des vaisseaux·2010
See all related articles

Mixed vasopressin receptor antagonists show promise for treating cardiac insufficiency by reducing pulmonary capillary pressure and increasing diuresis. Further studies are needed to confirm benefits in patient morbidity and mortality.

Area of Science:

  • Endocrinology
  • Nephrology
  • Cardiology

Context:

  • Neuro-hormonal systems, including vasopressin, are activated in cardiac insufficiency.
  • Vasopressin regulates blood osmolarity via V2 receptors and causes vasoconstriction through V1a receptors.

Purpose:

  • To evaluate the efficacy of specific and mixed vasopressin receptor antagonists in pathologies like SIADH, cirrhosis, and cardiac insufficiency.
  • To assess the potential of mixed anti-V1a-V2 antagonists as a therapeutic strategy for cardiac insufficiency.

Summary:

  • Mixed vasopressin receptor antagonists (anti-V1a-V2) appear more suitable than selective antagonists for cardiac insufficiency.
  • Early human studies indicate mixed antagonists reduce pulmonary capillary pressure and enhance diuresis and free water clearance.

Related Experiment Videos

Impact:

  • Encouraging preliminary results suggest a potential new therapeutic class for cardiac insufficiency.
  • Further research is crucial to confirm these findings and establish long-term benefits, including reduced morbidity and mortality.